stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.68
6.66
+6.94%
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Book value per share
Oruka Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 10.3×, down 54.6% from 22.8× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 17.7×. Over the past ten years it has ranged from 10.3× (fiscal 2025) to 1,308× (fiscal 2015) — the current reading is the lowest in ten years. Oruka Therapeutics, Inc. ranks 41st of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 10.3× | (54.55%) |
| FY2024 | 22.8× | (26.16%) |
| FY2023 | 30.8× | (11.20%) |
| FY2022 | 34.7× | (21.23%) |
| FY2021 | 44.1× | (62.84%) |
| FY2020 | 119× | 71.41% |
| FY2019 | 69.2× | (26.48%) |
| FY2018 | 94.1× | (55.76%) |
| FY2017 | 213× | (59.74%) |
| FY2016 | 528× | (59.61%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 17.7× | 100.95% |
| Mar 2026 | 8.8× | (14.73%) |
| Dec 2025 | 10.3× | (6.34%) |
| Sep 2025 | 11.0× | 35.32% |
| 42 more quarters | Free account |
Against its own ten years
Low 10.3×
High 1,308×
Ten-year median
69.2×
Current reading's percentile
9
Book value per share against peers
| Company | Book value per share |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 48.2× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 19.3× |
| ORKA Oruka Therapeutics, Inc. | 17.7× |
| CGON CG Oncology, Inc. compare | 11.7× |
| IMVT Immunovant, Inc. compare | 3.6× |
| IONS Ionis Pharmaceuticals, Inc. compare | 2.7× |
| AXSM Axsome Therapeutics, Inc. compare | 2.0× |
| KOD Kodiak Sciences Inc. compare | 1.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −0.8× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))